News | 16 August 2012
Many companies have been caught off-guard by the extent to which generic competition has eaten away at their sales. Genentech says it managed to be caught off-guard by a lack of it, leading to a shortage of the injectable version of its osteoporosis ...
Click on the link to read the full article at FiercePharma Manufacturing
(This link will open in a new window)